ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,227Medicare Part D Prescriptions Filled, Including Refills

Rank: 125 out of 1942

$434K Total Retail Price of All Prescriptions

Rank: 170 out of 1942

337 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
42% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Minnesota
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 337 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

11% of this provider’s 337 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 8,520 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 20%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Minnesota
SIMVASTATIN 439 394 1 1
FUROSEMIDE 397 384 2 5
OMEPRAZOLE 362 325 3 4
LEVOTHYROXINE SODIUM 356 332 4 3
LISINOPRIL 353 327 5 2
METFORMIN HCL 327 308 6 10
AMLODIPINE BESYLATE 297 281 7 6
ATORVASTATIN CALCIUM 210 200 8 14
TRAMADOL HCL 209 195 9 19
POTASSIUM CHLORIDE 205 205 10 17
DIGOXIN 196 196 11 40
METOPROLOL SUCCINATE 173 162 12 13
FENTANYL 170 146 S2 13 47
DONEPEZIL HCL 158 145 14 30
SERTRALINE HCL 146 134 15 20
CITALOPRAM HBR 146 135 15 15
LOSARTAN POTASSIUM 144 143 17 18
HYDROCHLOROTHIAZIDE 144 144 17 8
METOPROLOL TARTRATE 135 118 19 9
WARFARIN SODIUM 127 119 20 11
ISOSORBIDE MONONITRATE ER 122 122 21 42
NAMENDA 120 107 22 51
CRESTOR 114 114 23 34
ALENDRONATE SODIUM 106 106 24 21
BYSTOLIC 102 102 25 169
TAMSULOSIN HCL 100 100 26 29
POLYETHYLENE GLYCOL 3350 96 95 27 28
RANITIDINE HCL 90 74 28 31
RISPERIDONE 80 75 29 68
ENALAPRIL MALEATE 79 79 30 89
HYDROCODONE-ACETAMINOPHEN 78 62 S3 31 12
PREDNISONE 77 75 32 27
GABAPENTIN 75 69 33 16
ZOLPIDEM TARTRATE 74 71 34 25
ATENOLOL 74 72 34 7
JANUVIA 65 65 36 85
FLUDROCORTISONE ACETATE 60 60 37 256
LANTUS 56 56 38 49
DIOVAN 55 55 39 44
PANTOPRAZOLE SODIUM 53 53 40 48
LEVETIRACETAM 53 39 40 112
CLOPIDOGREL 52 49 42 55
SPIRIVA 51 45 43 57
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 18, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.